USRE40457EExpiredUtility

Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis

Assignee: VSL PHARMACEUTICALS INCPriority: Jun 28, 1996Filed: Jun 3, 1997Granted: Aug 12, 2008
Est. expiryJun 28, 2016(expired)· nominal 20-yr term from priority
A61P 37/04A61K 35/745A23L 29/065A61P 1/14A23C 9/1234Y10S435/975A61P 1/12A61K 35/744A23L 33/135A23V 2002/00A23V 2400/533A23V 2400/249
46
PatentIndex Score
4
Cited by
12
References
6
Claims

Abstract

Enteral compositions containing a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis , each at a concentration equal to or greater than 1×10 11 CFU per gram, are useful as adjuncts for enteral formulations and as oral nutritional supplements. The compositions can be administered before, during or at the end of an enteral formulation administration. The compositions can be administered separately or mixed with the enteral formulation. The compositions can also be employed at the end of the daily administration in order to prevent the colonization of the enteral tube by the other pathogens. The compositions can also be used as supplement to any liquid, creamy or pasty foodstuff.

Claims

exact text as granted — not AI-modified
1. An enteral dietary composition, comprising:
 a mixture of live lactic acid bacteria consisting of  Streptococcus thermophilus, Bifidobacterium longum  and  Bifidobacterium infantis , wherein the  Streptococcus thermophilus  concentration is at least 1×10 11  CFU per gram, the  Bifidobacterium longum  concentration is at least 1×10 11  CFU per gram, and the  Bifidobacterium infantis  concentration is at least 1×10 10  CFU per gram, each concentration based on the total composition.  
 
     
     
       2. The composition of  claim 1 , wherein the  Streptococcus thermophilus  concentration is 1×10 11  to 1×10 14  CFU per gram,  Bifidobacterium longum  concentration is 1×10 10  to 1×10 14  CFU per gram, and  Bifidobacterium infantis  concentration is 1×10 10  to 1×10 13  CFU per gram, each concentration based on the total composition. 
     
     
       3. The composition of  claim 1 , which is a liquid. 
     
     
       4. The composition of  claim 1 , which is a capsule. 
     
     
       5. A method for stimulating the immune system or modifying the composition of human intestinal flora in vivo, comprising:
 (a) preparing a composition containing a mixture of live lactic acid bacteria, said mixture consisting of  Streptococcus thermophilus, Bifidobacterium longum  and  Bifidobacterium infantis , wherein the  Streptococcus thermophilus  concentration is at least 1×10 11  CFU per gram wherein the  Bifidobacterium longum  concentration is at least 1×10 11  CFU per gram, and the  Bifidobacterium infantis  concentration is at least 1×10 10  CFU per gram, each concentration based on the total composition; and  
 (b) enterally administering the composition of (a) to a subject in need thereof, optionally mixed with a carrier.  
 
     
     
       6. A method for ameliorating diarrhea or intestinal disturbances in a patient in an enteral or parenteral diet feeding program, comprising:
 (a) preparing a composition containing a mixture of live lactic acid bacteria consisting of  Streptococcus thermophilus, Bifidobacterium longum  and  Bifidobacterium infantis , wherein the  Streptococcus thermophilus  concentration is at least 1×10 11  CFU per gram, the  Bifidobacterium longum  concentration is at least 1×10 11  CFU per gram, and the  Bifidobacterium infantis  concentration is at least 1×10 10  CFU per gram, each concentration based on the total composition, and  
 (b) administering the composition of (a) to said patient, optionally mixed with a carrier.

Join the waitlist — get patent alerts

Track USRE40457E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.